Epigenetic alterations play an important role in
carcinogenesis. Recent studies have suggested that global histone modifications are predictors of
cancer recurrence in various
tumor entities. Global
histone acetylation levels (
histone H3 lysine 9 acetylation [H3K9Ac],
histone H3 lysine 18 acetylation [H3K18Ac], total
histone H3 acetylation [H3Ac] and total
histone H4 acetylation [H4Ac]) were determined in patients with
renal cell carcinoma (RCC) using immunohistochemistry in a tissue micro array with 193 RCC and 10
oncocytoma specimens. The
histone acetylation pattern was not different among the diverse histological subtypes of RCC or
oncocytoma samples. The H3Ac levels were inversely correlated with pT-stage (P = 0.005), distant
metastasis (P = 0.036), Fuhrman grading (P = 0.001) and RCC progression (P = 0.029, hazard ratio 0.87). H4Ac deacetylation was correlated with pT-stage (P = 0.011) and grading (P = 0.029). H3K18Ac levels were an independent predictor of
cancer-progression following surgery for localized RCC in the univariate (P = 0.001, hazard ratio 0.78) and multivariate (P = 0.005, hazard ratio 0.82) analysis. In conclusion, our study supports the concept of global
histone modification levels as a universal
cancer prognosis marker, and provides evidence for the use of
histone deacetylases inhibitors as future drugs in the
therapy of RCC.